SCHEMBL3894397

SCHEMBL3894397

Cc1cc(F)c(F)c(C(F)(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 3/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CA2 P00918 1/20 0.34
POLB P06746 1/20 0.34
TYR P14679 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
AR P10275 3/20 0.32
KIF11 P52732 5/20 0.31
SYK P43405 1/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL83777 0.81 SMN1; SMN2 (0.34) RAPGEF4HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL18272234 0.81 HTR2A (0.39) RAPGEF4HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL13550091 0.81 RAPGEF4 (0.40) RAPGEF4HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL21892211 0.79 ALDH1A1 (0.33) RAPGEF4HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL24343525 0.77 SMN1; SMN2 (0.40) RAPGEF4HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL19268220 0.77 RAPGEF4 (0.41) RAPGEF4HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL79893 0.77 CYP11B1 (0.33) RAPGEF4HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL26712936 0.77 SMN1; SMN2 (0.41) RAPGEF4HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL465082 0.76 KIF11 (0.34) CYP11B1CYP11B2KIF11HSD11B1MPL
SCHEMBL12621 0.76 RAPGEF4 (0.52) RAPGEF4ALDH1A1CA2POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11664093-B2 Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-05-30 US disclosed
US-7959990-B2 Adjustment of liquid crystals; oligomers, dendrimers, or polymer in solution is applied to support; crosslinking by radiation or polarized light ROLIC AG (CH) 2011-06-14 US disclosed
US-7605134-B2 Pesticides MERIAL LIMITED (US) 2009-10-20 US disclosed
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2009-06-25 US disclosed
US-20080274304-A1 Functionalized Photoreactive Compounds ROLIC AG (CH) 2008-11-06 US disclosed
EP-1421094-B1 4\"-DEOXY-4\"-(S)-AMINO AVERMECTIN DERIVATIVES MERIAL LTD (GB) 2008-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, CHRM1, SRMS RAPGEF4 3540/4885HTR2A 423/4885HTR2C 830/4885
US-20080274304-A1 Functionalized Photoreactive Compounds PCNA, PIN1, MAP1LC3C RAPGEF4 1532/4885HTR2A 2854/4885HTR2C 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.